|Awarded On||May 20, 2020|
|Title||CARGo: a CAR-T cell program targeting HLA-G - a novel immune checkpoint and tumor specific antigen for advanced clear cell renal and ovarian carcinomas|
|Program||Product Development Research|
|Award Mechanism||Company Relocation|
|Institution/Organization||Invectys USA Inc|
|Principal Investigator/Program Director||Simon Wain-Hobson|
|Cancer Sites||Kidney and Renal Pelvis, Ovary|
*Pending contract negotiation
Invectys S.A. is a French biopharmaceutical company developing innovative anti-cancer products in immunotherapy based on leading technology from the Institut Pasteur in Paris. The Company is applying for a CPRIT relocation grant to advance its novel CAR-T platform to be able to conduct early stage clinical studies in Texas.
Invectys research is focused on the HLA-G molecule, a powerful modulator of the human immune system. It is the only cancer immunotherapy company focused on HLA-G: a highly significant and novel approach. HLA-G protects the fetus from the mother's immune system. However, in cancer tumors, cells are selected that express HLA-G to protect the tumor from attacks of the immune...